logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Bind Therapeutics, Inc.


USPTO Granted Patents = 27

% Expired Patents = 37.0



Forward Citations = 1,355

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Greg Troiano (20 out of 41 patents)

silverMedal Stephen E Zale (20 out of 50 patents)

bronzeMedal Mir Mukkaram Ali (16 out of 27 patents)

4.  James I Wright (16 out of 59 patents)

5.  Jeff Hrkach (10 out of 17 patents)

6.  Young-Ho Song (6 out of 19 patents)

7.  Christina Van Geen Hoven (6 out of 13 patents)

8.  Michael Figa (6 out of 9 patents)

9.  Abhimanyu Sabnis (6 out of 9 patents)

10.  David Dewitt (5 out of 10 patents)

11.  Maria Figueiredo (2 out of 6 patents)

12.  Jason Auer (2 out of 3 patents)

13.  Tarikh Christopher Campbell (2 out of 2 patents)

14.  Amy Grayson (2 out of 2 patents)

15.  Hong Wang (0 patent)


Core Competencies:
Polymeric Nanoparticles
Drug Loaded
Cancer Cell Targeting
Therapeutic Agents
High Throughput Fabrication
Sustained Release
Vinca Alkaloids
mTOR Inhibitors
Lyophilizing
Stable Formulations
Parenteral Administration
High Glass Transition Temperature

27 patents:

1. 9393310 - Drug loaded polymeric nanoparticles and methods of making and using same (2016-07-19),
2. 9375481 - Drug loaded polymeric nanoparticles and methods of making and using same (2016-06-28),
3. 9358215 - High throughput fabrication of nanoparticles (2016-06-07),
4. 9351933 - Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same (2016-05-31),
5. 9308179 - Long circulating nanoparticles for sustained release of therapeutic agents (2016-04-12),
6. 9295727 - Cancer cell targeting using nanoparticles (2016-03-29),
7. 9295649 - Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers (2016-03-29),
8. 9198874 - Long circulating nanoparticles for sustained release of therapeutic agents (2015-12-01),
9. 8956657 - Stable formulations for lyophilizing therapeutic particles (2015-02-17),
10. 8916203 - Stable formulations for lyophilizing therapeutic particles (2014-12-23),
11. 8912212 - Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers (2014-12-16),
12. 8905997 - Therapeutic particles suitable for parenteral administration and methods of making and using same (2014-12-09),
13. 8663700 - Drug loaded polymeric nanoparticles and methods of making and using same (2014-03-04),
14. 8652528 - Drug loaded polymeric nanoparticles and methods of making and using same (2014-02-18),
15. 8637083 - Stable formulations for lyophilizing therapeutic particles (2014-01-28),
Bind Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of targeted therapeutics using its proprietary AccuBIND technology. This innovative platform focuses on creating advanced drug delivery systems that enhance the efficacy and safety of treatments for various diseases, particularly in oncology. By leveraging its expertise in nanomedicine, Bind Therapeutics aims to revolutionize the way therapies are designed and administered, ultimately improving patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Bind Therapeutics, Inc.
27 Patents

#100 in Cambridge, MA

#740 in Massachusetts

#12,405 in US

#23,968 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Bind Therapeutics, Inc.

Forward Citations = 1,355

14 inventors:

goldMedal Greg Troiano (20 out of 41 patents)

silverMedal Stephen E Zale (20 out of 50 patents)

bronzeMedal Mir Mukkaram Ali (16 out of 27 patents)

4.  James I Wright (16 out of 59 patents)

5.  Jeff Hrkach (10 out of 17 patents)

Please report any incorrect information to [email protected]
Loading…